Science & Evidence

Ibogaine Research Database

86 peer-reviewed studies indexed from PubMed. Plain-language summaries where available.

All Studies (86)Opioid Addiction (15)Heroin Addiction (15)PTSD (15)Depression (15)Alcohol Addiction (15)Cocaine Addiction (15)Anxiety (13)Methamphetamine Addiction (12)Traumatic Brain Injury (2)

Studies on PTSD(7)

← Back to PTSD

Mystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans.

Brown, Lissemore, Shinozuka· Journal of affective disorders· 2026· PMID: 41265656

Ibogaine is an atypical psychedelic that evokes unique subjective effects, including mystical experiences. Mystical experiences have shown a mediating effect on clinical improvements following treatment with several psychedelic substances; however, the relationship between mystic...

Pharmacological Evaluation of Tropane Analogues at the Serotonin Transporter.

Avanes, Warren, Senthil· ACS chemical neuroscience· 2025· PMID: 40802711

Tropane alkaloids and their derivatives represent a diverse class of small molecules with a broad range of therapeutic applications. Many tropanes regulate synaptic levels of neuromodulators by interacting with monoamine transporters such as dopamine (DAT) and serotonin (SERT) tr...

Efficient and modular synthesis of ibogaine and related alkaloids.

Iyer, Favela, Domokos· Nature chemistry· 2025· PMID: 39915657

Anecdotal reports and preliminary clinical trials suggest that the psychoactive alkaloid ibogaine and its active metabolite noribogaine have powerful anti-addictive properties, producing long-lasting therapeutic effects across a range of substance use disorders and co-occurring n...

Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.

Gomez-Escolar, Folch-Sanchez, Stefaniuk· CNS drugs· 2024· PMID: 39033264

Mental health disorders and substance use disorders (SUDs) in particular, contribute greatly to the global burden of disease. Psychedelics, including entactogens and dissociative substances, are currently being explored for the treatment of SUDs, yet with less empirical clinical ...

What is needed for the roll-out of psychedelic treatments?

Xenakis, Shannon· Current opinion in psychiatry· 2024· PMID: 38726805

The pace of psychedelic treatments continues to increase. Regulation and coherent clinical guidance have not been established. A philosophical divide limits effective resolution of a practice delivery quandary: is this primarily a pharmacological or psychotherapeutic intervention...

The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.

Mastinu, Anyanwu, Carone· International journal of molecular sciences· 2023· PMID: 36674849

The need to identify effective therapies for the treatment of psychiatric disorders is a particularly important issue in modern societies. In addition, difficulties in finding new drugs have led pharmacologists to review and re-evaluate some past molecules, including psychedelics...

Neuroimaging in psychedelic drug development: past, present, and future.

Wall, Harding, Zafar· Molecular psychiatry· 2023· PMID: 37759038

Psychedelic therapy (PT) is an emerging paradigm with great transdiagnostic potential for treating psychiatric disorders, including depression, addiction, post-traumatic stress disorder, and potentially others. 'Classic' serotonergic psychedelics, such as psilocybin and lysergic ...